According to a new market report published by Transparency Market Research “Preimplantation Genetic Diagnosis Market - Asia Industry Analysis, Size, Share, Growth, Trends, and Forecast 2015 - 2023”, the PGD market in Asia was valued at US$ 16.0 Mn in 2014 and is projected to expand at a CAGR of 6.8% from 2015 to 2023 to reach US$ 28.8 Mn by 2023.

Preimplantation genetic diagnosis (PGD) is a reproductive technique that tests the chromosomes and genes of the embryos used in an intracytoplasmic sperm injection (ICSI), and can identify the presence of genetic anomalies, or aneuploidy. Demand for preimplantation genetic diagnosis is increasing among individuals who undergo IVF, as it reduces the chances of genetic disorders and disabilities rising in the child and improves the probability of live birth. The combination of preimplantation genetic diagnosis and IVF has curtailed the chances of passing on unsafe genetic materials to the embryo, thus refining the chances of successful pregnancy. Increasing incidence rate of genetic diseases is influencing patients to undergo PGD cycles for disease free offspring. Advanced techniques often lead to public unease, particularly when scientific and medical advances are moving ahead of public debate of the social and ethical concerns involved.

Read More: http://www.transparencymarketresearch.com/asia-preimplantation-genetic-diagnosis-market.html

Growing awareness among patients about the advantages of using preimplantation genetic diagnosis is expected to boost the preimplantation genetic diagnosis market in Asia in the next few years. The rising occurrence of genetic disorders is expected to contribute to the growth of the market in the region in the near future. Moreover, factors such as untapped opportunities in the health care sector, rising medical tourism, and increasing health care awareness are expected to propel the growth of the PGD market in Asia. The preimplantation genetic diagnosis market is witnessing significant growth in Southern (Southeast) Asia due to decline in the fertility rates, resulting in more number of people opting for assisted reproductive technologies. Moreover, rapid increase in health care infrastructure, rise in disposable income, and increasing awareness among the people boost market growth.

The preimplantation genetic diagnosis (PGD) market in Asia has been divided based on test type, end-user, and geography. Based on test type, the market has been segmented into aneuploidy screening, chromosomal aberrations, gender selection, HLA typing, single gene disorder, and X-linked diseases. The aneuploidy screening segment accounted for the largest share of 35% of the PGD market in Asia in 2014. Aneuploidy is an abnormal condition, wherein the number of chromosomes is either less or more. Aneuploidy screening reduces the probability of transferring an embryo with chromosomal abnormality. Based on end-user, the market has been segmented into fertility clinics, health care facilities (including hospitals, diagnostic centers, and health care facilities), and academic institutes and research centers.

Request A Sample Of This Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=9989

Usage of preimplantation genetic diagnosis for these applications has been increasing rapidly due to benefits associated with better pregnancy rate and birth of a healthy child. Aneuploidy screening using PGD has eased the method of detecting the risk of a syndrome caused due to variation in the number of chromosomes. Further research in this field has broadened the scope of applications of PGD in HLA typing, single gene disorder, and gender selection. Introduction of cost effective technologies, awareness and affordability of PGD tests are some of the recommendations provided for the market in Asia.

Major players in this market are Genesis Genetics (U.S.), Genea Limited (Australia), Illumina, Inc. (U.S.), Laboratory Corporation of America Holdings (U.S.), Natera, Inc. (U.S.), PerkinElmer, Inc. (U.S.), Quest Diagnostics Incorporated (U.S.), Reprogenetics (U.S.), and Reproductive Genetics Innovations LLC (U.S.).

The PGD market Asia has been segmented as follows:
•Asia Preimplantation Genetic Diagnosis (PGD) Market, by Test Type
oPGD for Aneuploidy Screening
oPGD for Chromosomal Aberrations
oPGD for Gender Selection
oPGD for HLA Typing
oPGD for Single Gene Disorder
oPGD for X-linked diseases

•Asia Preimplantation Genetic Diagnosis (PGD) Market, by End-user
oFertility Clinics
oHealth Care Facilities (including hospitals, diagnostic centers, and health care facilities)
oAcademic Institutes and Research Centers

•Asia Preimplantation Genetic Diagnosis (PGD) Market, by Geography
oSouth Eastern Asia
Indonesia
Malaysia
Philippines
Singapore
Thailand
Rest of SEA
oEastern Asia
China
Japan
South Korea
Rest of Eastern Asia
oSouthern Asia
India
Sri Lanka
Rest of Southern Asia
oCentral Asia
oWestern Asia
Israel
Turkey
Jordan
Saudi Arabia
United Arab Emirates
Rest of Western Asia

About Us
Transparency Market Research (TMR) is a global market intelligence company providing business information reports and services. The company’s exclusive blend of quantitative forecasting and trend analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information.

TMR’s data repository is continuously updated and revised by a team of research experts so that it always reflects the latest trends and information. With extensive research and analysis capabilities, Transparency Market Research employs rigorous primary and secondary research techniques to develop distinctive data sets and research material for business reports.

Contact us:
Mr. Sudip S
Transparency Market Research
90 State Street,
Suite 700,
Albany
NY - 12207
United States
Tel: +1-518-618-1030
USA - Canada Toll Free 866-552-3453
Email:Â [email protected]
Website: http://www.transparencymarketresearch.com/